DK1691833T3 - Præparater der omfatter polypeptider - Google Patents
Præparater der omfatter polypeptiderInfo
- Publication number
- DK1691833T3 DK1691833T3 DK04803302.1T DK04803302T DK1691833T3 DK 1691833 T3 DK1691833 T3 DK 1691833T3 DK 04803302 T DK04803302 T DK 04803302T DK 1691833 T3 DK1691833 T3 DK 1691833T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- binding sites
- polypeptides
- antigen binding
- compositions
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| PCT/EP2004/013445 WO2005052004A2 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1691833T3 true DK1691833T3 (da) | 2010-05-03 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04803302.1T DK1691833T3 (da) | 2003-11-28 | 2004-11-26 | Præparater der omfatter polypeptider |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (enExample) |
| EP (2) | EP1691833B1 (enExample) |
| AT (1) | ATE459374T1 (enExample) |
| AU (1) | AU2004293182B2 (enExample) |
| BE (1) | BE2016C023I2 (enExample) |
| CA (1) | CA2544532C (enExample) |
| CY (2) | CY1110689T1 (enExample) |
| DE (1) | DE602004025840D1 (enExample) |
| DK (1) | DK1691833T3 (enExample) |
| ES (1) | ES2341252T3 (enExample) |
| FR (1) | FR16C1000I2 (enExample) |
| HU (1) | HUS1600019I1 (enExample) |
| LU (1) | LU93067I2 (enExample) |
| NL (1) | NL300807I2 (enExample) |
| PL (1) | PL1691833T3 (enExample) |
| PT (1) | PT1691833E (enExample) |
| SI (1) | SI1691833T1 (enExample) |
| WO (1) | WO2005052004A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2383297B8 (en) | 2006-08-14 | 2023-03-22 | Xencor, Inc. | Optimized antibodies that target CD19 |
| ATE551071T1 (de) | 2006-09-08 | 2012-04-15 | Medimmune Llc | Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen |
| EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| ES2675299T3 (es) | 2010-10-27 | 2018-07-10 | Amgen Research (Munich) Gmbh | Medios y métodos para el tratamiento del LDLBG |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| CN103687872A (zh) | 2011-04-22 | 2014-03-26 | 新兴产品开发西雅图有限公司 | 前列腺特异性膜抗原结合蛋白和相关组合物以及方法 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP3083690A1 (en) | 2013-12-17 | 2016-10-26 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| EP3647324A1 (en) | 2013-12-17 | 2020-05-06 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| AU2015266797C1 (en) | 2014-05-29 | 2019-04-04 | Macrogenics, Inc. | Tri-Specific Binding Molecules that specifically bind to multiple Cancer Antigens and methods of use thereof |
| WO2016073791A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| ES2819256T3 (es) | 2014-11-05 | 2021-04-15 | Genentech Inc | Métodos para producir proteínas bicatenarias en bacterias |
| JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
| CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| PL3377103T5 (pl) | 2015-11-19 | 2025-07-07 | Revitope Limited | Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
| US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| JP7250674B2 (ja) | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| CA3039430A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
| MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| BR112020007630A2 (pt) | 2017-11-01 | 2020-11-17 | F. Hoffmann-La Roche Ag | anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| JP7159332B2 (ja) | 2018-03-13 | 2022-10-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ４－１ｂｂアゴニストと抗ｃｄ２０抗体の治療的組み合わせ |
| US12404328B2 (en) * | 2018-06-07 | 2025-09-02 | Cullinan Management, Inc. | Multi-specific binding proteins and methods of use thereof |
| CA3111809A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| TWI872030B (zh) | 2018-11-05 | 2025-02-11 | 美商建南德克公司 | 在原核宿主細胞中產生二鏈蛋白質之方法 |
| EP3962948A1 (en) | 2019-04-30 | 2022-03-09 | Amgen Research (Munich) GmbH | Means and methods of treating burkitt lymphoma or leukemia |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| CU20210096A7 (es) | 2019-05-21 | 2022-06-06 | Novartis Ag | Moléculas de unión a cd19 |
| AU2020403273A1 (en) | 2019-12-11 | 2022-06-30 | Cullinan Oncology, Inc. | Anti-CD19 antibodies and multi-specific binding proteins |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| KR20230025691A (ko) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | 삼중 음성 유방암을 치료하기 위한 방법과 조성물 |
| KR102453073B1 (ko) | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| KR20230152032A (ko) | 2021-02-03 | 2023-11-02 | 모차르트 쎄라퓨틱스 인코포레이티드 | 결합제 및 이를 사용하는 방법 |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| EP4329800A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| EP4496631A1 (en) | 2022-03-23 | 2025-01-29 | F. Hoffmann-La Roche AG | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| AU2023251832A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| JP2025541593A (ja) | 2022-11-03 | 2025-12-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ１９／抗ｃｄ２８二重特異性抗体による併用療法 |
| AU2024275646A1 (en) | 2023-05-24 | 2025-11-13 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| US20250115680A1 (en) | 2023-09-26 | 2025-04-10 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| WO1992015682A1 (en) | 1991-02-27 | 1992-09-17 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| SI1071752T1 (en) * | 1998-04-21 | 2003-12-31 | Micromet Ag | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
-
2004
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en not_active Ceased
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I2/el unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT1691833E (pt) | 2010-06-08 |
| NL300807I2 (enExample) | 2016-10-13 |
| LU93067I2 (fr) | 2016-07-11 |
| ES2341252T3 (es) | 2010-06-17 |
| AU2004293182A1 (en) | 2005-06-09 |
| CA2544532A1 (en) | 2005-06-09 |
| PL1691833T3 (pl) | 2010-08-31 |
| WO2005052004A3 (en) | 2006-03-09 |
| CY1110689T1 (el) | 2015-06-10 |
| FR16C1000I1 (enExample) | 2016-06-24 |
| AU2004293182B2 (en) | 2010-02-18 |
| US20070249529A1 (en) | 2007-10-25 |
| SI1691833T1 (sl) | 2010-06-30 |
| ATE459374T1 (de) | 2010-03-15 |
| DE602004025840D1 (de) | 2010-04-15 |
| EP1691833A2 (en) | 2006-08-23 |
| CA2544532C (en) | 2015-06-16 |
| EP2186527A1 (en) | 2010-05-19 |
| FR16C1000I2 (fr) | 2017-02-03 |
| EP1691833B1 (en) | 2010-03-03 |
| CY2016010I1 (el) | 2016-08-31 |
| US10000574B2 (en) | 2018-06-19 |
| CY2016010I2 (el) | 2016-08-31 |
| BE2016C023I2 (enExample) | 2023-12-18 |
| HUS1600019I1 (hu) | 2016-06-28 |
| WO2005052004A2 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1691833T3 (da) | Præparater der omfatter polypeptider | |
| CY1118951T1 (el) | Χρηση αντισωματων υποδοχεα ιντερλευκινης-4 και συνθεσεις αυτων | |
| CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| ATE469176T1 (de) | Modifizierter anti-tnf antikörper | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| WO2003011895A8 (en) | Compositions and methods for modulation of immune responses | |
| WO2004035603A3 (en) | Erythropoietin receptor binding antibodies | |
| DE60142342D1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
| CY2014038I2 (el) | Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| NO20041325L (no) | Substanser | |
| ATE446972T1 (de) | Il-1 bindende antikörper und fragmente davon | |
| BRPI0511008A (pt) | agentes de ligação de il-13 | |
| WO2002036625A3 (en) | Prokineticin polypeptides, related compositions and methods | |
| EP1322747A4 (en) | IMPROVED FORMULATIONS USING THERMAL SHOCK / STRESS PEPTIDE-PROTEIN COMPLEXES | |
| WO2002076406A3 (en) | Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them | |
| NO20033260D0 (no) | Materialer omfattende sykloheksamantan | |
| EA200400384A1 (ru) | Растворимый рецептор т-клетки | |
| ES1050709U (es) | Elemento para el apilado de barricas perfeccionado. |